ECP 2022 Final Programme

Poster Sessions a Tuesday 104 Tuesday, 6 Sept PS-15 PS-16 021 Proof of concepts for automated extrac- tion of mutation status from narrative pathology reports: KRAS G12C mutations and NTRK fusions in non-squamous non-small cell lung cancer Vincent De Jager, The Netherlands B. Cajiao Garcia, B. Koopman, V. Stangenberger, R. Rijnders, R. de Valk, E. Schuuring, S. Willems, L. van Kempen 022 KRAS-G12C mutation in non-small cell lung cancer: prevalence and prognostic significance Víctor Cristóbal Redondo, Spain V. Pedrero, D. Parra Trujillo, C. Alenda González, F. Aranda López 023 Genomic profile of primary non-small cell lung cancer and matched mediastinal lymph nodes by next-generation sequencing: a pilot study Leila Antonangelo, Brazil C. Faria, R. Terra, E. do Nascimento, E. de Mello, F. Mangone, M. Nagai, M. Agati, V. Capelozzi 024 Concordance between FISH and NGS in detecting t(11;14) status in patients with multiple myeloma Raphaele Thiebaut, France H. Avet-Loiseau, X. Li, J. Ross, C. Hader 025 Stability of t(11;14) status by FISH between diagnosis and relapse in patients with multiple myeloma Jeremy Ross, USA H. Avet-Loiseau, R. Thiebaut, X. Li, C. Hader 026 The frequency of EGFR mutations of non-small cell lung carcinomas in the east Black Sea region of Turkey Zeynep Sagnak Yilmaz, Turkey Z. Turkmen Usta, S. Aydin Mungan, S. Ersoz 027 Tumour PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced non small cell lung cancer (NSCLC) Patients Tzahi Neuman, Israel G. Vainer, A. Horesh 028 Identification of Maml1 as a novel negative regulator of Itch E3 ubiquitin ligase activity: new insights in cancer biology Sabrina Zema, Italy M. Pelullo, A. Montalti, M. De Carolis, A. Villari, I. Screpanti, D. Bellavia 029 Characterising the cellular architecture of the tumour microenvironment using imag- ing mass cytometry and digital image analysis with the HALO® and HALO AI™ platform Ghislaine Lioux, USA K. Collins, N. Carmell 030 Genomic landscape analysis of ERBB3-mutated human cancers reveals common co-occurrence with activating ERBB2 alterations Igor Odintsov, USA R. Somwar, M. Ladanyi 031 Mir-9 and their putative targets expres- sion in prostate cancer Ines Benedetti, Colombia L. Barrios, J. Rebollo PS-16 Poster Session Poster Session Pulmonary Pathology Chair: Katrien Grünberg, The Netherlands 001 Clinicopathological features of primary pulmonary Hodgkin lymphoma: a multicenter study and literature review of 110 cases Hera Jung, Republic of Korea T. Lee 002 Five-year experience of evaluation of PD-L1 expression on advanced non-small cell lung carcinoma – single centre study Jelena Stojsic, Serbia